Invited Review

The Relationship Between Maternal Antidepressants and Neonatal Hypoglycemia: A Systematic Review


Department of Psychiatry, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey

Alpha Psychiatry 2021; 22: 224-229
DOI: 10.5152/alphapsychiatry.2021.21143
Read: 482 Downloads: 113 Published: 09 July 2021

The aim of the article is to review systematically current researches investigating the relationship between intrauterine exposure to antidepressants and neonatal hypoglycemia. This paper included studies published in electronic databases from January 2005 to July 2020. The searched keywords were as follows: antidepressants, pregnancy, selective serotonin reuptake inhibitors (SSRIs), citalopram, fluoxetine, paroxetine, escitalopram, sertraline, fluvoxamine, selective serotonin-norepinephrine reuptake inhibitors (SNRIs), venlafaxine, tricyclic antidepressants (TCAs), neonatal outcomes, neonatal hypoglycemia, imipramine, clomipramine, amitriptyline, bupropion, trazodone, and mirtazapine. This review examined 10 relevant studies. The odds ratio/risk ratio reported in the studies were 1.33-1.73 for any antidepressant, 1.30-1.35 for SSRI, 1.42-2.11 for SNRI, and 2.07 for TCAs. The risk of neonatal hypoglycemia in infants exposed to maternal TCAs appears to be slightly higher compared to infants exposed to maternal SSRIs. Data from current studies consistently show that exposure to maternal antidepressants during pregnancy may
be related to increased risk of neonatal hypoglycemia in infants.

Cite this article as: Uguz F. The relationship between maternal antidepressants and neonatal hypoglycemia: a systematic review. Alpha Psychiatry. 2021;22(5):224-229.

EISSN 2757-8038